Effects of 5'-DFUR and lentinan on cytokines and PyNPase against AH66 ascites hepatoma in rats

Anticancer Research

Volumn 19, Issue 1 A, 1999, Pages 375-379

  Ogawa, Tetsushi ^a   Ohwada, Susumu ^a   Sato, Yoshihiro ^a   Izumi, Masaru ^a   Nakamura, Seiji ^a   Takeyoshi, Izumi ^a   Kawashima, Yoshiyuki ^a   Ohya, Toshihiro ^a   Koyama, Toru ^a   Morishita, Yasuo ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

5' DFUR; AH66; Ascites hepatoma; Cytokines; Lentinan; PyNPase

Indexed keywords

CYTOKINE; DOXIFLURIDINE; IMMUNOSTIMULATING AGENT; LENTINAN; PYRIMIDINE ANTAGONIST; PYRIMIDINE NUCLEOSIDE PHOSPHORYLASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; ASCITES HEPATOMA; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOKINES; FLOXURIDINE; LENTINAN; LIVER NEOPLASMS, EXPERIMENTAL; MALE; PENTOSYLTRANSFERASES; RATS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032923113     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Cook AF, Holman MJ, Kramer MJ, Trown PW: Fluorinated pyrimidine nucleosides, 3, Synthesis and antitumor activity of a series of 5′-deoxy-5-fluoropyrimidinenucleosides. J Med Chem 22: 1330-1335, 1979.
2. Kim JP, Kwon OJ, Oh ST, Yang HK: Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann Surg 216: 269-279, 1992.
3. Uchida A, Hoshino T: Clinical studies on cell-mediated immunity in patients with malignant disease, 1. Effect of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsiveness in vitro. Cancer 45: 476-483, 1980.
4. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A, Maruyama HB: Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann 71: 112-123, 1980.
5. Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y, Ishitsuka H: Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull 31: 175-178, 1983.
6. Eda H, Fujimoto K, Watanabe S, Ishikawa T, Ohiwa T, Tatsuno K, Tanaka Y, Ishitsuka H: Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5′-deoxy-5-fluorouridine. Jpn J Cancer Res 84: 341-347, 1993.
7. Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y, Wada K, Ishitsuka H: Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 32: 333-338, 1993.
8. Hamuro J, Röllinghoff M, Wagner H: Induction of cytotoxic peritoneal exudate cells by T-cell immune adjuvants of the β (▶3) glucan type lentinan and its analogues. Immunology 39: 551-559, 1980.
9. Herberman RB, Nunn-Hargrove ME: Augmentation of natural killer (NK) cell activity by lentinan. In: Aoki T (ed) Manipulation of host defence mechanisms. Excerpta Medica, Amsterdam, p188-193, 1981.
10. Miyakoshi H, Aoki T: Acting mechanisms of lentinan in human-II. Enhancement of non-specific cell-mediated cytotoxicity as an interferon inducer. Int J Immunopharmac 6: 373-379, 1984.
11. Hamuro J, Röllinghoff M, Wagner H: β (1 ▶3) glucan-mediated augmentation of alloreactive murine cytotoxic T-lymphocytes in vivo. Cancer Res 38: 3080-3085, 1978.
12. Hamuro J, Chihara G: Lentinan, a T-cell-oriented immunopotentiator: its experimental and clinical applications and possible mechanism of immune modulation. In: Feniche RL (ed) Immune modulation agents and their mechanisms, Dekker, New York, p409-437, 1985.
13. Suzuki M, Takatsuki F, Maeda YY, Hamuro J, Chihara G: Antitumor and immunological activity of lentinan in comparison with LPS. Int J Immunopharmac 16: 463-468, 1994.
14. Arinaga S, Karimine N, Takamuku K, Nanbara S, Inoue H, Nagamatsu M, Ueo H, Akiyoshi T: Enhanced induction of lymphokine-activated killer activity after lentinan administration in patients with gastric carcinoma. Int J Immunopharmac 14: 535-539, 1992.
15. Yoshimoto R, Akiyama Y, Hayami T, Iguchi Y, Izawa M, Hamuro J: Augmentation of interleukin 1 production by antitumor polysaccharide, lentinan and its role in the generation of effector T cells against tumors. Int J Immunopharmac 4: 267, 1982.
16. Arinaga S, Karimine N, Takamuku K, Nanbara S, Nagamatsu M, Ueo H, Akiyoshi T: Enhanced production of interleukin 1 and tumor necrosis factor by peripheral monocytes after lentinan administration in patients with gastric carcinoma. Int J Immunopharmac 14: 43-47, 1992.
17. Takeshita K, Hayashi S, Tani M, Kando F, Saito N, Endo M: Monocyte function associated with intermittent lentinan therapy after resection of gastric cancer. Surg Oncol 5: 23-28, 1996.
18. Ogawa T, Ohwada S, Morishita Y: Immunochemotherapy with 5′-deoxy-5-fluorouridine and streptococcal preparation OK-432 against AH66 ascites hcpatoma in rats. Ann Cancer Res Ther 4: 21-24, 1995.
19. Ohwada S, Ogawa T, Izumi M, Inoue T, Teshigawara O, Ikeya T, Kusaha T, Roppongi T, Iino Y. Morishita Y: Effects of 5′-DFUR and OK-432 on cytokines and thymidine phosphorylase in tumor tissue of gastric cancer patients. Anticancer Res 17: 2313-2318, 1997.
20. Lawrence DA: Transforming growth factor-β: a general review. Eur Cytokine Netw 7: 363-374, 1996.
21. Kloen P Gebhardt MC, Perez-Atayde A, Rosenberg AE, Springfield DS, Gold LI, Mankin HJ: Expression of transforming growth factor-β (TGF-β) isoforms in osteosarcomas: TGF-β 3 is related to disease progression. Cancer 80: 2230-2239, 1997.
22. Friess H, Yamanaka Y, Büchler M, Ebert M, Beger HG, Gold LI, Korc M: Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterol 105: 1846-1856, 1993.
23. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, Imai Y, Shimomukai H, Nomura Y, Matsuda Y, Matsuzawa Y: High levels of transforming growth factor β1 in patients with colorectal cancer: association with disease progression. Gastroentcrol 110: 375-382, 1996.
24. Roberts AB, Thompson NL, Heine U, Flanders C, Sporn MB: Transforming growth factor-β: possible roles in carcinogenesis. Br J Cancer 57: 594-600, 1988.
25. Roberts AB, Sporn MB: Physiological actions and clinical applications of transforming growth factor-β (TGF-β). Growth Factors 8: 1-9, 1993.
26. Ueki N, Nakazato M, Ohkawa T, Ikeda T, Amuro Y, Hada T, Higashino K: Excessive production of transforming growth factor-β1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim Biophys Acta 1137: 189-196, 1992.